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Patients diagnosed with lung squamous cell carcinoma (LUSC) have limited targeted
therapies. We report here the identification and characterisation of BCL11A, as a LUSC
oncogene. Analysis of cancer genomics datasets revealed BCL11A to be upregulated in LUSC
but not in lung adenocarcinoma (LUAD). Experimentally we demonstrate that non-
physiological levels of BCL11A in vitro and in vivo promote squamous-like phenotypes,
while its knockdown abolishes xenograft tumour formation. At the molecular level we found
that BCL11A is transcriptionally regulated by SOX2 and is required for its oncogenic functions.
Furthermore, we show that BCL11A and SOX2 regulate the expression of several transcription
factors, including SETD8. We demonstrate that shRNA-mediated or pharmacological inhibi-
tion of SETD8 selectively inhibits LUSC growth. Collectively, our study indicates that BCL11A
is integral to LUSC pathology and highlights the disruption of the BCL11A–SOX2 transcrip-
tional programme as a novel candidate for drug development.
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Lung cancer accounts for the highest rate of cancer-relateddiagnosis and mortality worldwide1. Broadly, there are twomajor types of lung cancers; small cell lung cancer (SCLC)
accounting for 15% of cases and non-small cell lung cancer
(NSCLC) accounting for 85% of cases1. NSCLC patients have a
poor outcome in the clinic with only 15% of patients surviving
5 years or more2. At present NSCLC is defined histo-
pathologically in the clinic into four broad categories: lung ade-
nocarcinoma (LUAD), lung squamous cell carcinoma (LUSC),
large cell carcinoma and undifferentiated NSCLC. LUAD and
LUSC are the most common types of NSCLC (90% of cases).
LUSC accounts for more than 400,000 deaths worldwide each
year3 and unlike LUAD there are limited targeted therapies
available for LUSC. Platinum-based chemotherapy remains the
first-line treatment for LUSC and although the recent FDA
approval of Necitumumab in combination with platinum-based
chemotherapy for metastatic LUSC has shown positive signs, a
great deal of work still needs to be done in this field4.
At the cellular level, LUAD tends to originate from the secre-
tory epithelial cells in the lung while LUSC usually originates
from basal cells (BCs) in the main and central airways2. At the
molecular level LUAD is known to harbour mutations in epi-
dermal growth factor receptor (EGFR), V-Ki-Ras2 Kirsten Rat
Sarcoma Viral Oncogene Homologue (KRAS) and Anaplastic
Lymphoma Receptor Tyrosine Kinase (ALK), which are also well
modelled and studied both in vitro and in vivo (for review see
refs. 5,6). On the other hand, LUSC is less studied but it is known
that amplifications of Sex Determining Region Y (SRY)-Box 2
(SOX2) tend to be present in 70–80% of patients7–10. We report
here the identification and characterisation of the transcriptional
regulator, BCL11A as a LUSC oncogene. We demonstrate that
along with SOX2, it regulates key epigenetic factors, and that the
disruption of one of these factors, SETD8 leads to selective affects
in LUSC cells compared to LUAD cells. By disrupting the
BCL11A-SOX2 transcriptional programme, our results provide a
potential future framework for tackling the unmet clinical need
for LUSC patients.
Results
BCL11A is a LUSC oncogene. Recently, a detailed picture of the
molecular differences between LUAD and LUSC has been made
available through ‘The Cancer Genome Atlas’ (TCGA)11,12. To
identify key drivers responsible for the differences between LUAD
and LUSC we reanalysed the gene expression data from TCGA
and focused on transcriptional regulators in the genome. As
reported previously SOX2 was the most amplified gene in LUSC
and its expression level was also significantly higher in LUSC vs.
LUAD (Fig. 1a and Supplementary Fig. 1a). The second most
amplified locus in LUSC patients revealed by TCGA analysis
contains the transcription factors BCL11A and REL11,12. BCL11A
has been shown to be an oncogene in B-cell lymphoma and triple
negative breast cancer13–16.
We found that BCL11A expression levels were also significantly
higher in LUSC vs. LUAD (Fig. 1a and Supplementary Fig. 1a).
Moreover, the expression of both BCL11A and SOX2 was
significantly higher in LUSC but not in LUAD tumour samples
compared to patient matched normal samples (Fig. 1b, c and
Supplementary Fig. 1b–c) supporting a driver role for these
transcription factors in LUSC pathology. In contrast, REL
expression was unchanged between LUSC and LUAD (Fig. 1a–c
and Supplementary Fig. 1a–c) suggesting that BCL11A
amplification is a key driving event in LUSC. This observation
is supported by the recent report from the TRACERx (TRAcking
Cancer Evolution through therapy (Rx)) study demonstrating the
amplification of BCL11A as an early event in LUSC17.
Furthermore, BCL11A IHC staining on LUAD (n= 99) and
LUSC (n= 120) TMAs revealed little or no staining in 99% of
LUAD patients. In contrast, 25% of LUSC patients had moderate
staining and 24% of LUSC patients had strong staining, which is
in agreement with previous IHC staining of NSCLC tumours18
(Fig. 1d). This confirms our transcriptomic analyses indicating
the specificity of BCL11A in LUSC patients.
To determine if high levels of BCL11A expression are
oncogenic in LUSC, we performed shRNA-mediated knockdown
(KD) of BCL11A using two independent shRNAs in two LUSC
cell lines, LK2 and H520 (Supplementary Fig. 2a and b). We first
tested the clonogenic capacity of control or BCL11A-KD cells by
seeding them into matrigel for 3D colony formation assays. We
found that BCL11A-KD cells had a significant reduction in colony
formation capacity (Supplementary Fig. 2c and d). We then
injected control or BCL11A-KD cells into immune compromised
mice to test for their tumour formation capacity and found a
significant reduction in tumour burden from BCL11A-KD cells
compared to control cells (Fig. 1e, f). In addition, we found the
squamous markers KRT5 and TP63 levels were significantly
reduced in BCL11A-KD LUSC cells (Supplementary Fig. 2e–h).
However, we found no change in the expression of SOX2 in
BCL11A-KD LUSC cells suggesting that BCL11A activity is
downstream of SOX2 (Supplementary Fig. 2i and j). Moreover, to
test if the role of BCL11A is context dependant, we knocked
down BCL11A in a LUAD cell line H1792 and found no change
in 3D colony growth indicating specificity at the cellular level
(Supplementary Fig. 2k–l).
BCL11A overexpression leads to thickening of the airways. To
explore the role of BCL11A in lung biology, we utilised a novel
Cre-inducible mouse model that allows for the overexpression of
BCL11A. Essentially, BCL11A was inserted into the Rosa26 locus
with a LoxP-Stop-LoxP (LSL) cassette upstream, under the con-
trol of a CAGG promoter, thus preventing the expression of
BCL11A unless the LSL is excised by Cre recombinase. To test
the effect of BCL11A overexpression on lung morphology, we
allowed the BCL11A-overexpression (BCL11Aovx) mice to inhale
Adenovirus-Cre (Fig. 2a). Eight months after infection, we ana-
lysed the lungs and found signs of airway hyperplasia (Fig. 2b, c)
accompanied by aggregates of small hyperchromatic cells with
irregular nuclei that represent reserve cell hyperplasia (Fig. 2b,
arrows and inset), which are precursors to squamous metapla-
sia19. IHC analysis of the lungs from BCL11Aovx also indicated an
increase in positivity for the proliferative marker Ki-67 (Supple-
mentary Fig. 3a) and Sox2 indicating a transition to squamous
differentiation (Supplementary Fig. 3b). However, we found
little difference in Cc10, Krt5 and Trp63 staining at this stage
(Supplementary Fig. 3a and b).
To further investigate the role of BCL11A in LUSC, we
employed a 3D organoid culture system for BCs from the
trachea, as they have been suggested to be the cell of origin for
LUSC20–22. BCs from human and mouse lungs have higher
expression of BCL11A when compared to the other epithelial
compartments indicating its importance in lung biology (Supple-
mentary Fig. 4a and b)22. Therefore, we crossed the BCL11Aovx
mice to R26-CreERT2 mice, which allowed us to induce Cre
recombination by the administration of tamoxifen. In addition,
we also used a Bcl11a conditional knockout mouse under the
control of R26-CreERT2 (called Bcl11aCKO from this point) to
elucidate the importance of BCL11A in tracheosphere organoid
formation (Fig. 2a).
We found that in contrast to the hollow organoids normally
formed by BCL11AOVX or Bcl11aCKO organoids treated with
ethanol in vitro, BCs from BCL11Aovx mice treated with
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tamoxifen in vitro formed solid organoid structures with no
hollow lumen suggesting hyper-proliferation and loss of organi-
sation (Fig. 2d). However, BCs from Bcl11acko mice failed to form
any organoid structures suggesting that Bcl11a is necessary for
organoid formation (Fig. 2d). Quantitative analysis revealed a
significant decrease in organoid numbers from Bcl11acko BCs but
no significant difference in BCL11Aovx BCs (Supplementary
Fig. 4c and d). Tamoxifen or ethanol-treated organoids from
WT mice showed no difference in organoid morphology
indicating that the differences are attributed to changes in
BCL11A expression (Supplementary Fig. 4e)
H&E staining confirmed the hollowness of the organoids from
the control mice which was in stark contrast to the filled
organoids from the BCL11Aovx mice (Fig. 2e and Supplementary
Fig. 5). IF staining revealed that the BCL11Aovx organoids were
also positive for Ki-67 (Supplementary Fig. 5), Sox2, Krt5, Trp63
and negative for the luminal marker Krt8 (Fig. 2e and
Supplementary Fig. 6) indicating that BCL11A maintains a
squamous phenotype.
BCL11A and SOX2 occupy common loci in LUSC cells. Given
the importance of SOX2 in driving LUSC8,9 we next investigated if
BCL11A is regulated by SOX2. To achieve this, we knocked down
SOX2 (SOX2-KD) in two LUSC cell lines using two independent
shRNAs (Fig. 3a, b and Supplementary Fig. 7a and b). Similar to
BCL11A we found that SOX2-KD cells had a significantly reduced
colony and tumour formation abilities (Supplementary Fig. 7c–f).
At the molecular level we found a significant reduction in the
expression levels of BCL11A and similar to BCL11A-KD, reduction
in squamous markers KRT5 and TP63 in the SOX2-KD cells
(Fig. 3c, d and Supplementary Fig. 7g–j).
To investigate if BCL11A is required for SOX2-mediated
oncogenesis we introduced a doxycycline inducible BCL11A
overexpression vector into SOX2-KD cell lines and found that
BCL11A overexpression partially rescues the colony and tumour
formation abilities of SOX2-KD cells (Fig. 3e–h, and Supplemen-
tary Fig. 8a–c). These results suggest that BCL11A is partially
responsible for SOX2’s-mediated transcriptional changes in
LUSC cells.
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Fig. 1 BCL11A is a lung squamous cell carcinoma (LUSC) oncogene. a Volcano plots of The Cancer Genome Atlas (TCGA) RNAseq data11, 12 indicating that
BCL11A and SOX2 are highly expressed in LUSC compared to lung adenocarcinoma (LUAD). The plots show that REL is not differentially expressed in LUSC
vs. LUAD patients. The x-axis represents log2 expression fold-change (FC) in LUSC patients vs. LUAD patients and the y-axis represents –log10(pValue).
The vertical dashed lines represent FC= 1.0 and the horizontal dashed line represents p-value= 0.01. b Volcano plots indicating that BCL11A and SOX2 are
differentially expressed in LUSC patients vs. matched normal samples. The plot indicates that REL is not differentially expressed in LUSC vs. matched
normal samples. c Volcano plots indicating that neither BCL11A, SOX2 nor REL are differentially expressed in LUAD patients vs. matched normal. d Images
and scoring of BCL11A IHC staining on LUAD and LUSC tumours (see Methods for scoring). e, f Graphs depicting reduction in tumour size observed when
shRNA1 or shRNA2 against BCL11A-transfected LK2 (e) and H520 (f) cells are injected subcutaneously into mice compared to control. Five mice per cell
line were monitored for 25 days after which tumours were removed and measured. On the right are images showing actual tumours measured. The box
plot extends from 25th to 75th percentile and the line represents the median. Data presented as mean ± s.d. One-way ANOVA with post Dunnett test
performed, *p < 0.05, **p < 0.005, and ***p < 0.001
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To understand how BCL11A and SOX2 contribute to the LUSC
transcriptional programme we performed BCL11A and SOX2
ChIP-Seq analysis on LK2 cells in the presence or absence of
BCL11A (BCL11A-KD) (Fig. 3i). We identified 49,567 peaks for
SOX2 and 4294 peaks for BCL11A (Fig. 3j and Supplementary
Data 1 and 2). Out of the 4294 BCL11A peaks identified, 3946
were not present in BCL11A-KD cells validating the true nature
of BCL11A binding at these regions of the genome.
We then compared regions bound by both BCL11A and
SOX2 in LK2 control cells and identified 1114 peaks suggesting
that a relationship between these two transcription factors (Fig. 3i,
j). Subsequently, we identified the nearest genes to the common
peaks (Supplementary Data 3) and performed Gene Ontology
(GO) analysis to identify if these common peaks are enriched for
specific biological process (Fig. 3j). The top hits from the GO
analysis revealed enrichment for transcriptional and epigenetic
regulators including SETD8, SKIL, and TBX2 (Fig. 3k, l). These
three factors have been reported to have roles in NSCLC. SKIL and
TBX2 have been reported to be upregulated in NSCLC23,24.
SETD8 on the other hand has been indirectly linked to NSCLC as
a target of mir-382 in NSCLC25. We also found that SOX2 binds
the BCL11A locus at multiple sites suggesting a strong direct
regulation at the transcriptional level further supporting the data
in Fig. 3c, d–l. BCL11A and SOX2 peaks on SETD826,27, SKIL28,
TBX229 and BCL11A were validated and confirmed by ChIP-
qPCR (Supplementary Fig. 9). The overlap of the ChIP-Seq peaks
suggests a direct interaction between BCL11A and SOX2 proteins,
which was confirmed in co-immunoprecipitation experiments on
LK2 and H520 (Supplementary Fig. 10a, b).
BCL11A and SOX2 regulate SETD8 gene expression. To
further assess the importance of these three factors we first
analysed the expression of SETD8, SKIL and TBX2 in
multiple NSCLC cell lines and found that SETD8 and SKIL
expression was significantly higher in LUSC cell lines (n= 5)
compared to LUAD cell lines (n= 6) (Fig. 4a, b) which was
in correlation with the expression levels of BCL11A and
SOX2 (Fig. 4d, e). In contrast, TBX2 levels were not different
in LUSC cell lines vs. LUAD cell lines (Fig. 4c). To understand
if BCL11A regulates these genes, we sorted basal stem cells (Epcam
+ve/GSIβ4+ve)30,31 and Epcam+ve cells from trachea excised from
tamoxifen-treated BCL11Aovx or WT mice (Fig. 4f, g and k). We
found that Setd8 and Skil, but not Tbx2 and Sox2 are upregulated in
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both basal stem cell and epithelial cell compartment from the tra-
chea of BCL11Aovx mice (Fig. 4g–k and l–p). These results provide
the first evidence that BCL11A regulates Setd8 and Skil independent
of SOX2-driven mechanisms.
We then investigated the expression of SETD8, SKIL and TBX2 in
BCL11A-KD or SOX2-KD cells and found a modest reduction in the
expression of these genes in BCL11A-KD, which was more
pronounced in SOX2-KD cells (Supplementary Fig. 10c–n). We
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reasoned that this could be due to SOX2 redundantly regulating
Setd8 in BCL11A-KD cells.
SETD8 KD selectively inhibits LUSC tumour growth. Collec-
tively, our results thus far suggest that disrupting the BCL11A-
SOX2 transcriptional programme could be selectively detri-
mental to LUSC cells. To test this hypothesis we employed a
dox-inducible shRNA system32, to KD SETD8, SKIL and TBX2
in two LUSC cell lines and one LUAD cell line (H520
Supplementary Fig. 11a, b, and c; LK2 Supplementary Fig. 11d, e,
and f; H1792 Supplementary Fig. 11g, h, and i). We found that
SETD8-KD had a pronounced effect on colony formation
selectively in LUSC cells but not in LUAD cells (Fig. 5a, e, i).
SKIL-KD, also reduced colony formation but affecting both
LUSC and LUAD cells suggesting its importance in NSCLC
(Fig. 5b, f, g). In contrast, TBX2-KD had no effect on either
LUSC or LUAD cells suggesting that it does not play a key role in
the pathology of these cells (Fig. 5c, g, k).
Fig. 3 BCL11A and SOX2 occupy independent and common loci in the genome of LUSC cells. a and bWestern blot showing SOX2 and BCL11A expression in
SOX2-KD in LK2 (a) and H520 (b) cells transfected with control (scramble), shRNA1 or shRNA2 vectors. c and d BCL11A expression in SOX2-KD LK2
(c) and H520 (d) cells. e Western blot showing BCL11A rescue in SOX2-KD cells. Doxycycline (Dox) inducible BCL11A overexpression vector was
transfected into control and SOX2 shRNA1 LK2 cells and Dox treatment was performed for 48 h. f Graph depicting 3D matrigel assay in control, SOX2-KD
and BCL11A rescue cells indicating a partial rescue in SOX2-KD, BCL11A overexpressing cells. g Graph indicating partial rescue of tumour size from BCL11A
overexpressing SOX2-KD cells injected subcutaneously. The whiskers indicate the range of the data and the line represents the median. h Images of actual
tumours measured. Four mice per cell line were monitored for 15 days after which tumours were removed and measured. Data presented as mean ± s.d.
(n= 4). One-way ANOVA test performed, *p < 0.05, **p < 0.005, and ***p < 0.001. i LK2 cell line either transfected with control or shRNA1 vectors
were used for BCL11A and SOX2 ChIP-Seq. Heatmaps showing BCL11A only, SOX2 only or common peaks in BCL11A or SOX2 IP in control and BCL11A-KD
cells. j Venn diagram indicating the overlap of BCL11A and SOX2 target genes in LK2 cells. BCL11A target genes were derived by BCL11A IP in LK2 control
cells. SOX2 target genes were derived from SOX2 IP in LK2 control cells. Image below show top five biological GO terms from GO analysis performed using
DAVID. k and l IGV genome browser views for SETD8, SKIL, TBX2 and BCL11A
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Given the selectivity of the SETD8-KD on LUSC vs. LUAD,
we decided to focus on this gene for further studies. SETD8
is a member of the SET domain containing family and is known
to catalyse the monomethylation of histone H4 Lys2026,27 which
is involved in recruiting signalling proteins or chromatin
modifications33. In agreement with the qPCR data from sorted
BCL11Aovx cells (Fig. 4) we found that SETD8 protein levels were
upregulated in airways and hyperplastic lesions of BCL11Aovx
mice (Supplementary Fig. 12a, b). Furthermore, analysis of the
TCGA datasets revealed that SETD8 expression correlates with
BCL11A and SOX2 expression in LUSC patients (Supplementary
Fig. 12c and d).
To test the impact of SETD8 on xenograft tumour growth we
injected cells with either Scram or SETD8 shRNA vectors into
immune compromised mice. Once tumours reached 0.25 cm2 in
size, we supplemented the mouse diet with doxycycline to induce
the SETD8 KD and measured tumour growth periodically. This
setup would also mimic a therapeutic intervention in patients
presenting with LUSC tumours. We found that initial tumour
growth rates were comparable between Scram and shRNA cells
across all three cell lines (Fig. 5d, h and l and Supplementary
Fig. 13a–c) However, upon the addition of doxycycline tumours
from tumours formed by the SETD8-KD cells slowed down
significantly (Fig. 5d, h, and l). At the end of the experiment,
tumours formed by the SETD8-KD were ∼50% smaller in size
compared to Scram cells (Fig. 5d, h and l and Supplementary
Fig. 13a–c). Interestingly, this effect was only found in the LUSC
cell lines and not the LUAD which, is in agreement with the
colony assays results.
SETD8 inhibition sensitises LUSC cell lines to chemotherapy.
To expand our analysis further, we tested the effect of a SETD8
inhibitor, NSC66328434, on 11 NSCLC cell lines (5 LUSC and 6
LUAD) in vitro. We treated all the NSCLC cell lines with a range
of NSC663284 concentrations (full details of setup in Materials
and methods) for 72 h and measured cell viability. Remarkably,
we found that LUSC cells had significantly lower IC50 (average
0.30 μM) compared to LUAD cells (average 7.65 μM) (Fig. 6a, b).
To understand if SETD8 inhibition would add a clinical benefit
to patients, we tested the effect of combining NSC663284 and
cisplatin. First, we found that cisplatin treatment for 24 h alone
affected LUSC and LUAD in a similar way with both cell
types demonstrating a similar IC50 (LUAD= 64.12 μM and
LUSC= 31.67 μM) (Fig. 6c, d). However, if we pre-treat NSCLC
cell lines with NSC663284 for 48 h and then combine cisplatin
with NSC663284 for a further 24 h we found that LUSC (IC50=
4.66 μM) cells are more sensitive to cisplatin than LUAD cells
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(IC50= 32.21 μM) (Fig. 6e, f). It is important to note that
NSC663284 has also been reported as an inhibitor of Cdc2535–37.
However, our shRNA data which is SETD8 specific corroborate
the NSC663284 data and strongly supports the case for exploring
SETD8 as a novel target for LUSC treatment alone or in com-
bination with other chemotherapeutics.
Discussion
Currently there is an unmet clinical need for patients with LUSC.
Understanding and developing therapies for LUSC lags behind
LUAD largely due to the association between tobacco smoking
and LUSC incidences. Indeed, cancer genomics studies such as
TCGA and TRACERx show that generally LUSC have a
mutational signature associated with smoking12,17. However,
even with the decrease in smoking rates LUSC incidences are still
high38, reinforcing the calls for better molecular understanding
and the development of new therapies to tackle the disease. In this
study, we have demonstrated that the transcription regulator,
BCL11A is upregulated in LUSC vs. LUAD and that it is a direct
target of SOX2. BCL11A was initially discovered as an oncogene
in B-Cell lymphomas39 and we have recently reported that it is as
an oncogene in TNBC13. We show that BCL11A upregulation
leads to early stages of tumour development in the mouse and is
critical for tumour maintenance even in the presence of SOX2.
Our data suggests that disrupting the BCL11A-SOX2 transcrip-
tional programme might provide a selective therapeutic window
for LUSC patients. This was demonstrated by the sensitivity of
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LUSC cell lines to the inhibition of SETD8, a gene we identified to
be regulated by both BCL11A and SOX2 specifically in LUSC.
SETD8 is a member of the SET domain containing family and is
known to catalyse the monomethylation of histone H4 Lys2026,27,
which is involved in recruiting signalling proteins or chromatin
modifications33. In addition, SETD8 has been shown to play a
role in maintaining skin differentiation40 and is dysregulated in
multiple cancer types41–43. We found that Setd8 was also upre-
gulated in the mouse model of BCL11A overexpression in the
lung. It will be important in the future to investigate the down-
stream targets of Setd8 and their role in LUSC development. In
conclusion, our results describe an oncogenic role for BCL11A in
LUSC and provide a potential future framework for tackling the
unmet clinical need for LUSC patients.
Methods
Mouse models. All mice used in this study were maintained at the Sanger Institute
or the University of Cambridge. Housing and breeding of mice and experimental
procedures were performed according to the UK 1986 Animals Scientific Procedure
Act and local institute ethics committee regulations. The BCL11Aovx allele was
generated following a strategy previously described44. Briefly, the ROSA26 allele
was targeted with a construct containing human BCL11A cDNA preceded by a
loxP flanked STOP cassette and marked eGFP under the control of an internal
ribosomal entry site (IRES) downstream of the inserted cDNA and transgene
transcription is controlled by the CAGG promoter. The generation of the Bcl11acko
mice was described previously16. All mice were 8–12 weeks of age at the time of
experiments, and at least three mice per cohort were used in each experiment. The
primers used for genotyping are listed in Supplementary Data 4.
Tracheal and BASC isolation and tracheoshpere culture. Tracheae were incu-
bated in 50 Uml−1 dispase (Sigma) for 45 min at 37 °C. 10 ml PBS was injected
through each trachea using a 25 G 5/8″ needle to flush out sheets of epithelial cells.
Cells were incubated in 0.25% trypsin for 5 min at 37 °C.
For isolating basal stem cells, mice were first injected intraperitoneally with
tamoxifen (Sigma) dissolved in corn oil. Trachea was isolated as described above
and cells were stained in PBS+ 10%FBS with 1:500 anti-EpCAM BV421
(Biolegend) and GSIβ4-Biotin. BCs were considered Epcam+ve/GSIB4+ve 30,31.
Cells were sorted directly into RLT lysis buffer for mRNA isolation.
For tracheosphere culture, cells were stained in PBS+ 10%FBS+ 1:100 anti-
EpCAM PE-Cy7 (Biolegend)+ 1:5000 DAPI on ice for 20 min. Live EpCAM+ve
cells were isolated using a MoFlo sorter. 2500 cells were plated in 100 μl 1:1 mix of
mouse tracheal epithelial cell (MTEC)/plus media which is DMEM-Ham’s F-12
(1:1 vol/vol), 15 mM HEPES, 3.6 mM sodium bicarbonate, 4 mM L-glutamine,
100 Uml−1 penicillin, 100 μg ml−1 streptomycin, and 0.25 μg ml−1 fungizone;
supplemented with 10 μg ml−1 insulin, 5 μg ml−1 transferrin, 0.1 μg ml−1 cholera
toxin, 25 ng ml−1 epidermal growth factor (Becton-Dickinson, Bedford, MA, USA),
30 μg ml−1 bovine pituitary extract, 5% FBS, and freshly added 0.01 μM retinoic
acid45 and growth factor reduced-Matrigel (Corning) per 24-well insert, in
duplicate with 500 nM 4-hydroxy tamoxifen (Sigma) or ethanol (vehicle) for each
mouse, and cultured for 15 days.
Cell lines. LK2, NCI-H520 and LUDLU1 cells were generously gifted to us by
Dr. Frank McCaughan. NCI-H157, SW900, NCI-H1792, NCI-H522, NCI-HCC78,
A549, NCI-H1563 and NCI-H1975 were obtained from the Sanger Cancer Project.
All these cells were all maintained in RPMI 1640 (Gibco), 10% FCS and 1%
Penicillin/streptomycin in a 37 °C incubator with 5% CO2. All cell lines were
routinely tested for mycoplasma.
ShRNA-mediated KD. BCL11A shRNA sequences were obtained from TRC
consortium (TRCN0000033449 and TRCN0000033453) and cloned into a piggyBac
transposon vector (PB-H1-shRNA-GFP) as describe previously13. Sox2 shRNA
sequences (TRCN0000355694 and TRCN0000257314) were also cloned as above.
H520, H1792 and LK2 cells were transfected with 4 μg of respective vector using
Lipofectamine 3000 or Lipofectamine LTX (Invitrogen). Cells were treated with
G418 (400 μg ml−1) (Gibco) for 5 days after which GFP+ve cell were sorted using
the Sony SH800Z sorter and cultured.
Doxycycline inducible shRNA-mediated KD. SETD8 shRNA (TRCN0000359304
and TRCN0000359373), SKIL shRNA (TRCN0000431894 and TRCN0000424201);
and TBX2 shRNA (TRCN0000232147 and TRCN0000232146) were cloned into
pLKO-Tet-On vector32. Lentiviruses were generated by co-transfecting
HEK293T cells with 3 μg of shRNA-encoding plasmid and 1 μg each of pMD2.G,
pMDLg/pRRE and pRSVRev plasmids using Lipofectamine LTX. Growth media
was exchanged after 5 h and lentivirus-containing supernatant was harvested after
48 h. The supernatant was filtered using a 0.45 μm filter cartridge and then Lenti-X
concentrator was added. The solution was incubated O/N at 4 oC and then cen-
trifuged at 1500×g for 45 min. The pellet was then resuspended in 1/20th of the
original volume using RPMI media. Cells were then infected with the virus for 48 h
and selected in 1 μg ml−1 puromycin. Cells infected with virus were grown in
RPMI supplemented with 10% Tet-spproved FBS (Clontech) and 1 μg ml−1 pur-
omycin. shRNA expression was induced by culturing cells in the presence of 1 μg
ml−1 doxycycline for 72 h.
Transfection and 3D colony assays. The control or the BCL11A overexpression
piggybac vectors were delivered into NSCLC cells using Lipofectamine LTX
(Invitrogen). Transfected cells were maintained for 48 h and then cultured in
puromycin (1 μg ml−1). To induce BCL11A expression in LK2 SOX2-KD cells,
doxycycline (Clonetech) was used at a final concentration of (1 μg ml−1). 3D
colony assays were performed by suspending 500 cells in matrigel (BD Biosciences)
and seeding this cell-matrigel suspension onto a six-well plate. The plate was then
incubated for 15 min in 37 °C/5% CO2 to allow hardening of suspension. Growth
media was added to the well and changed every 2–3 days for 20 days. All
experiments were performed in triplicates.
Preparation of RNA. RNA was extracted using the RNeasy mini kit (Qiagen). Cell
cultures in T25 flasks were first washed with cold PBS, and 350 μl of RLT was
added. Cells were scraped, passed through a 20 G syringe five times and RNA was
extracted using the RNeasy mini kit (Qiagen) according to manufacturer instruc-
tions. DNA was degraded by adding 20U Rnase-free DnaseI (Roche) for 30 min at
room temperature. DnaseI treatment was performed on columns.
Preparation of cDNA and qRT-PCR. 1 μg of total RNA was diluted to a final
volume of 11 μl. 2 μl of random primers (Promega) were added after which the
mixture was incubated at 65 °C for 5 min. A master mix containing Transcriptor
Reverse Transcriptase (Roche), Reverse Transcriptase buffer, 2 mM dNTP mix and
RNasin Ribonuclease Inhibitors (Promega). This mixture was incubated at 25 °C
for 10 min, then 42 °C for 40 min and finally 70 °C for 10 min. The resulting cDNA
was then diluted 1:2.5 in H2O for subsequent use. qPCR was performed using a
Step-One Plus Real-Time PCR System (Thermofisher Scientific). Either Taqman
(ThermoFisher Scientific) probes with GoTaq Real Time qPCR Master Mix
(Promega) or primers (Sigma) with PowerUp SYBR Green Master Mix (Ther-
moFisher Scientific) were used. All probe and primer details can be found in
Supplementary Data 5 and 6. The enrichment was normalised with control mRNA
levels of GAPDH and relative mRNA levels were calculated using the ΔΔCt method
comparing to control group.
Western blot. Cells were lysed using RIPA (Cell signalling) and protease inhibitors
(Roche) as per manufacturer instructions. Total protein was measured using the
bicinchoninic acid (BCA) method (Pierce Biotechnology). In total, 50 mg cell lysate
was separated using 7.5% SDS–PAGE gels and transferred to PVDF membranes by
electro-blotting. Membranes were blocked in 5% (w/v) milk in Tris-buffered saline
containing 0.1% Tween-20 (TBST). Blots were then incubated at 4 °C overnight
with primary antibodies as indicated, washed in TBST and subsequently probed
with secondary antibodies for 1 h at room temperature. ECL solution was then
added to the membrane and analysed. Antibodies used were, anti-BCL11A
(ab191401, Abcam, 1:3000), anti-SOX2 (ab97959, Abcam, 1:2000) and anti-
TUBULIN (ab7291, Abcam, 1:10000). All the original western blot images can be
found in Supplementary Figures 14 and 15.
Co-immunoprecipitation. Cells were lysed using RIPA (Cell signalling) and pro-
tease inhibitors (Roche) as per the manufacturer’s instructions. Total protein was
measured using the BCA method as above (Pierce Biotechnology). Briefly, 500 µg
cell lysates were pre-cleared for 3 h at 4 °C to remove nonspecific binding. Then,
the pre-cleared lysates were incubated with anti-BCL11A (Bethyl, A300–382A) and
SOX2 (R&D Systems, AF2018) or control IgG at 4 °C overnight. Next day 50 µl of
Dynabeads Protein G (Thermo Fisher Scientific) were added to each sample. After
3 h, the complex was washed three times with RIPA buffer, and then analysed by
Western Blot performed as described above.
Histology and immunohistochemistry and immunofluorescence. Cultured
organoid were fixed with 4% paraformaldehyde in PBS for 4 h at room tempera-
ture. After rinsing with PBS, fixed colonies were immobilised with Histogel
(Thermo Scientific) for paraffin embedding. 5 μm sections of lung tissues or
embedded colonies were stained with haematoxylin and eosin (H&E) and
immunostained with antibodies for BCL11A (IHC—ab191402, Abcam, 1:1000),
SOX2 (IHC—ab97959, Abcam, 1:1000; IF—14-9811-82, eBioscience, 1:200), Ki67
(IHC—MA5-14520, Thermo Scientific, 1:1000; IF—ab16667, Abcam, 1:300), GFP
(IF—ab13970 Abcam, 1:1000), Keratin 8 (IF—TROMA-I, DSHB, 1:100), Keratin 5
(IHC—ab52635, Abcam, 1:1000; IF—905501, Biolegend, 1:1000), P63 (IHC—
ab735, Abcam, 1:200; IF—ab735, Abcam, 1:200), CCP10 (IHC—sc25555, Santa
Cruz Biotechnology, 1:500), SETD8 (IF—ab3798, Abcam 1:100). IHC secondary
staining involved an HRP-conjugated donkey anti-rabbit or donkey anti-mouse
secondary (1:250, Thermo Scientific) and were detected using DAB reagent
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(Thermo Scientific). IF secondary staining involved goat anti-chicken 488, goat
anti-rabbit 647, goat anti-rat 647, goat anti-rabbit 488 and goat anti-mouse 647
(1:2000, Invitrogen). Nuclear stain was detected using Haematoxylin (IHC) or
ProLong Gold Antifade Mountant DAPI (Thermofisher, P36941) (IF). IHC images
were acquired using a Zeiss Axioplan 2 microscope and IF images were acquired
using a Leica TCS SP5 confocal microscope and analysed on Image J.
Xenograft tumour assays. One million H520 and LK2 cells were suspended in
25% matrigel (BD Biosciences) and HBSS. This mixture was subcutaneously
injected in 6–12-week-old NSG mice. To induce BCL11A overexpression in SOX2-
KD xenografts or to induce shRNA expression, mice were fed doxycycline pellets
(Envigo, TD.01306, 625 mg/kg). Mice were randomised to receive injections of
either control or shRNA-KD cells in the xenograft experiment. Tumours were
measured blindly by animal technicians who did not know what was injected into
the specific mouse. Mice were culled as specified in figure legends and resulting
tumours were analysed.
ChIP-Seq and ChIP-qPCR. ChIP-Seq experiments were performed as described46.
Antibodies used were BCL11A (Bethyl, A300-382A) and SOX2 (R&D Systems,
AF2018). Briefly 2 × 15 cm plates per cell line were formaldehyde crosslinked,
nuclear fraction was isolated and chromatin sonicated using Bioruptor Pico
(Diagenode). IP was performed using 100 μl of Dynabeads Protein G (Thermo
Fisher Scientific) and 10 μg of antibody. The samples were then reverse crosslinked
and DNA was eluted using Qiagen MinElute column. Sample was then processed
either for sequencing or qPCR. Primers used for qPCR are listed in Supplementary
Data 6.
Drug assays. SETD8 inhibitor NSC663284 (Cayman Chemical Company, 13303)
was suspended using DMSO in 10 mM stock concentration. Cisplatin (LKT
Laboratories, C3374) was suspended in 154 mM NaCl at a 3 mM stock con-
centration. Cells were cultured as above and seeded at 1000 cells per 96-well plate
and left to recover for 24 h. The edges of the 96-well plate were avoided to ensure
accuracy in measurement. For NSC663284, an initial dilution of 1:100 from stock
was performed in RPMI media for the first concentration of 10–4M. Half log
dilutions were performed in RPMI media reaching 10–6M and after which full log
dilutions were performed reaching 10–10M. For cisplatin, initial dilution in RPMI
media were made to achieve 100 and 75 μM. The 100 μM solution was used to
make the following solutions 50, 25, 12.5, 6.75, 3.75, 1.5, and 0.5 μM. Cells were
treated with vehicle for 48 h after which the above doses of cisplatin were added.
For cisplatin+NSC663284 experiment the NSC663284 IC50 concentration for
each cell line was calculated and added initially for 48 h and then added again along
with the cisplatin dilution series as above for 24 h. Data analysis for drug inhibitor
assays was performed in GraphPad Prism 7.02 (San Diego, CA). Data were fitted to
obtain concentration–-response curves using the three-parameter logistic equation
(for pIC50 values). Emax was constrained to 100% while the basal (Emin) para-
meter was contrained to 20%. Statistical differences were analysed using one-way
ANOVA or Student’s t-test as appropriate with post hoc Dunnett’s multiple
comparisons, and p < 0.05 was considered significant.
BCL11A IHC on patient tumours. TMAs contained LUAD (n= 99) and LUSC
(n= 120) cases of archival primary pulmonary tumours collected under East
Midlands NRES REC approved project (ref. 14/EM/1159). 1 mm (n= 3) cores are
present per case which were initially scored (average nuclear staining intensity) as
0= neg, 1=weak, 2=moderate, 3= strong. A median score was calculated for
each case and re classified as 0= neg, 1=moderate, 2= strong. All tissues and
data are anonymised to the research team. IHC was performed using BCL11A
antibody (ab19487, 1:200) with CC1 antigen retrieval using a Ventana discovery xt.
Digital images of stained TMAs were scanned with a Nanozoomer RX instrument
and scored on-screen by MD.
TCGA gene expression analysis. The TCGA data was accessed from the recount2
database47 containing gene level count data from RNA-seq and clinical data from
primary tumour samples from patients diagnosed with LUAD and LUSC,
respectively. EdgeR48 was used to test for differential expression of transcription
factors (as defined by Tfcheckpoint.org). For this, compositional differences
between samples were normalised using the trimmed median of M-values method
and a gene-specific dispersion was estimated for each gene. A negative binomial
generalised log-linear model was fit to each gene with the covariates “plate+
disease_type” (for the LUAD versus LUSC comparison) or “patient+ dis-
ease_type” (for the tumour versus normal comparison). A log-likelihood ratio test
was conducted to test whether the coefficient of the disease_type variable is non-
zero, followed by Benjamini–Hochberg adjustment of p values to account for
multiple testing. Plate A277 and A278 from the LUAD dataset were removed prior
to analysis as they showed a clear separation along the first component in a
principal component analysis from all other LUAD samples.
ChIP-Seq analysis. ChIP-Seq libraries were sequenced on illumina Hiseq2000
platform at the Wellcome Sanger Institute. Each library was divided into two and
sequenced on different lanes. Reads were subsequently run through a pipeline at
the sequencing facility to remove adaptor sequences and align to the reference
genome among others. Alignment was done using mem algorithm in BWA
(version 0.7.15) and human_g1k_v37 was used as the reference genome. Aligned
and processed reads were received as compressed CRAM files. Samtools (version
1.3.1) was used to decompress the CRAM files and filter uniquely mapped reads in
proper pairs. Next, reads from the two runs were combined into a single BAM file
using ‘merge’ function in samtools. Bedtools intersect was then used to remove
reads falling into blacklisted genomic regions or unplaced genomic contigs of the
GRCh37 assembly before marking and removing duplicate reads using MarkDu-
plicates function in Picard tools. Next, DownsampleSam in picard tools was used to
sample ~105 million reads from each BAM file. Significantly enriched genomic
regions relative to input DNA were identified using MACS2 (version
2.1.1.20160309) with p-value cutoff of 1.00e−05. Heatmaps generation: Mapped
read counts were calculated in a 10 bp window and normalised as reads per
kilobase per million (RPKM mapped reads) using bamCoverage module from
deeptools (version 2.5.1)49. This coverage file was used to compute score matrix ±
1 kb around peak summits using computeMatrix reference-point module (from
deeptools version 2.5.1)49. Heatmaps of binding profiles around peak summits
were then generated using plotHeatmap module in deeptools (version 2.5.1)49.
Number of overlapping peaks between BCL11A and SOX2 and nearest down-
stream genes to peaks were determined using ODS and NDG utilities, respectively,
in PeakAnnotator (version 1.4). For annotating nearest downstream genes, Homo
sapiens GRCh37 (release 64) from ensembl was used.
Code availability. Source code will be available on request.
Data availability. The Chipseq data is available from ArrayExpress (accession
numbers: # E-MTAB-6958) . The authors declare that all remaining data sup-
porting the findings of this study are available within the article and its Supple-
mentary Information files or from the authors upon request.
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